文献速递前列腺癌

经会阴与经直肠磁共振成像融合引导前列腺穿刺活检的前列腺癌检出与并发症比较

Prostate Cancer Detection and Complications of Transperineal Versus Transrectal Magnetic Resonance Imaging-fusion Guided Prostate Biopsies.
PubMed 文献 · Urology · 2023-04-13

该回顾性研究纳入2020年8月至2021年8月接受经会阴或经直肠磁共振成像融合靶向穿刺并同步系统随机穿刺的361例男性,比较两种入路对临床显著前列腺癌的检出率和30天并发症率。结果显示经直肠组检出率47.2%、经会阴组48.6%(P=0.78),并发症率无差异(P=0.45),按既往穿刺状态分层亦无显著差异。

要点

  • 经直肠与经会阴磁共振成像融合靶向穿刺的临床显著前列腺癌检出率无显著差异(47.2% vs 48.6%,P=0.78)。
  • 两种入路的30天并发症率无显著差异(P=0.45)。
  • 按主动监测、既往阴性活检及初次活检状态分层,检出率均无显著差异。

核心结论

  • 经直肠与经会阴磁共振成像融合靶向穿刺在临床显著前列腺癌检出率及并发症率上均无显著差异,按既往活检或主动监测状态分层亦无差异。

研究设计与样本

  • 回顾性识别2020年8月至2021年8月接受经会阴或经直肠磁共振成像融合靶向穿刺并同步系统随机穿刺的男性,共纳入361例患者。

主要发现

  • 经直肠磁共振成像靶向穿刺检出临床显著前列腺癌47.2%,经会阴磁共振成像靶向穿刺检出48.6%(P=0.78)。
  • 主动监测患者中两种入路检出率无显著差异(P=0.59)。
  • 既往阴性活检患者中两种入路检出率无显著差异(P=0.34)。
  • 初次活检患者中两种入路检出率无显著差异(P=0.19)。
  • 两种入路的并发症率无显著差异(P=0.45)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the rates of detection of clinically significant prostate cancer (csPCa) and complications associated with transperineal (TP) and transrectal (TR) biopsy approaches to magnetic resonance imaging (MRI)-fusion targeted biopsy. MATERIALS AND METHODS: We retrospectively identified men who underwent TP or TR MRI-targeted biopsy with concurrent systematic random biopsy from August 2020 to August 2021. Primary outcomes were detection rates of csPCa and 30-day complication rates between the 2 MRI-biopsy groups. Data were additionally stratified by prior biopsy status. RESULTS: A total of 361 patients were included in the analysis. No demographic differences were observed. No significant differences were observed between TP and TR approaches on any of the outcomes of interest. TR MRI-targeted biopsies identified csPCa in 47.2% of patients, and TP MRI-targeted biopsies identified csPCa in 48.6% of patients (P = .78). No significant differences were observed in csPCa detection between the 2 approaches for patients on active surveillance (P = .59), patients with prior negative biopsy (P = .34), and patients who were biopsy naïve (P = .19). Complication rates did not vary by approach (P = .45). CONCLUSION: Neither the identification of csPCa by MRI-targeted biopsy nor rates of complications differed significantly based on a TR or TP approach. No differences were seen between MRI-targeted approaches based on prior biopsy or active surveillance status.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Buller D, Sahl J, Staff I, et al. Prostate Cancer Detection and Complications of Transperineal Versus Transrectal Magnetic Resonance Imaging-fusion Guided Prostate Biopsies. Urology. 2023. PMID: 37059232. doi:10.1016/j.urology.2023.04.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。